Compare SAP SE (SAP) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SAP SE vs Sanofi SA — how do they compare? SAP SE trades at $154.29 (market cap $183.83B), while Sanofi SA trades at $44.05 (market cap $104.83B). The key difference: SAP SE is the larger of the two by market cap, and Sanofi SA pays the higher dividend (5.5%). Which is the better fit depends on your goals.
| SAP | SNY | |
|---|---|---|
Market Cap | $183.83B | $104.83B |
Sector | Technology | Health |
52-Week High | $307.27 | $52.34 |
52-Week Low | $148.06 | $41.33 |
Enterprise Value | $181.35B | $121.32B |
Dividend Yield | 1.85% | 5.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SAP trades at $154.34, down 2.96% on the day, amid bearish technical signals despite strong fundamentals. The company reported robust earnings beats in recent quarters with Q1 2026 EPS of $2.01 exceeding expectations of $1.92. Revenue growth remains solid at $36.8B for 2025, with a healthy net income margin of 19.58%. Analyst consensus remains positive with a $222.33 price target, though technical indicators show resistance near $157.
SAP presents a compelling investment case with strong profitability metrics and consistent earnings outperformance. However, near-term technical weakness and competitive pressures in the cloud software space pose risks. The stock's current discount to analyst targets offers potential upside for patient investors focused on the company's AI transformation and cloud growth trajectory.
SNY trades at $43.76, down 2.02% today, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 results pending. Revenue grew to $46.72B in 2025, with net income margin improving to 16.72%. Recent positive developments include FDA approval for Sarclisa's wearable injector and EU approval for Cenrifki in multiple sclerosis.
Outlook remains positive with analyst consensus leaning toward buy/hold, though regulatory scrutiny in the EU presents near-term risk. The stock offers a solid dividend yield with the upcoming $2.42 payment. Valuation metrics like P/E of 19.5 and P/B of 1.27 suggest reasonable pricing relative to peers, supported by robust cash flow from operations of $10.75B.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About SAP SE
Founded in 1972 by former IBM employees, SAP provides database technology and enterprise resource planning software to enterprises around the world. Across more than 180 countries, the company serves 440,000 customers, approximately 80% of which are small to medium-size enterprises.
Read more on SAP →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
